The US Department of Defense has awarded a collaborative grant to Transcend Therapeutics and Yale University (US).
The grant is to fund the preclinical research of Transcend’s lead candidate, methylone for treating post-traumatic stress disorder (PTSD). The funding builds on Yale University’s $1m Department of Defense (DoD) grant to study the mechanism of action of methylone and midomafetamine (MDMA) in PTSD.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Methylone (TSND-201) is a rapid-acting neuroplastogen (a biological substrate not a therapeutic).
Transcend is conducting a placebo-controlled Phase I/II trial (NCT05741710) in the UK to evaluate the safety and efficacy of methylone in treating patients with severe PTSD.
Part A of the study was an open-label study and was expected to enrol up to 15 participants with PTSD. Top-line data from this part is expected by the end of this year. Part B of the trial will be a randomised, double-blind, placebo-controlled study enrolling up to 64 patients.
Transcend’s co-founder and medical adviser for the US Department of Veterans Affairs National Center for PTSD stated: “There is a tremendous demand, especially among veterans, for new and effective treatments for PTSD.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMultiple PTSD treatments currently in development include Halucenex’s synthetic psilocybin, which showed a 40% reduction in PTSD symptoms in the Phase II trial. Bionomics is expected to announce the Phase IIb trial (NCT04951076) results for BNC210 in Q3 2023. BNC210 is a negative allosteric modulator of the α7 nicotinic acetylcholine receptor and has received a fast track designation from the Food and Drug Administration (FDA) for treating PTSD.
The US DoD has also sponsored a PTSD Phase II trial (NCT05422612) for the combination therapy of Idorsia Pharmaceuticals’ Quviviq (daridorexant), fluoxetine and vilazodone hydrochloride.
